Arca
Skip to content
Tools
Tools

Cimilre Dual Max

Pump, Breast, Powered. 510(k) K260643, from Cimilre Co., Ltd. (Cheonan-Si, Chungcheongnam-Do,, KR). Product code HGX, class 2.

As of Nov 18, 2026, K260643 is an FDA 510(k) held by Cimilre Co., Ltd., substantially equivalent on Aug 21, 2026 after 175 days, with no recalls tied to it in FDA's recall database.

  • Substantially equivalent: Aug 21, 2026
  • Review time: 175 days
  • Recalls: 0

Indications for Use

As the 510(k) summary states them, read from FDA's summary PDF

The Cimilre Dual Max is a powered breast pump intended to express and collect milk from the breasts of lactating women. The Cimilre Dual Max is intended for multiple users and single user in home and healthcare environments.

Predicate Devices

The legally marketed devices this 510(k) summary says it is substantially equivalent to, read from FDA's summary PDF
  • VivaceK242111 · Unimom.Co · Feb 6, 2025

Other HGX Clearances

The newest 510(k)s for the same product code; their median review was 127 days; see every HGX device

Record

Type
Traditional
Received
Feb 27, 2026
Review panel
Obstetrics/Gynecology
Regulation
21 CFR 884.5160

One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.